openPR Logo

Press Releases from Dasatinib - Pharma Proff (1 total)

Dasatinib - Drug Insight and Forecast, 2018

Dasatinib (Sprycel) medicines are generally used to treat people with chronic myeloid leukemia and people with acute lymphoblastic leukemia who have been tested positive for the Philadelphia chromosome (Ph+). Developed by Bristol-Myers Squibb Company, Dasatinib has been approved by the FDA for the treatment of pediatric patients aged one-year-old with newly diagnosed Ph+ acute lymphoblastic leukemia in combination with chemotherapy. Download the sample report @ The clinical trials have shown

Go To Page:   1 2 3 4 5 6 7 8 9 10